New drug targets Hard-to-Treat cancers in early trial
NCT ID NCT07046923
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 26 times
Summary
This study tests a new drug called LY4175408 in people with advanced lung, endometrial, or triple-negative breast cancers that have not responded to standard treatments. The drug is designed to seek out and attack cancer cells carrying a specific marker (PTK7). The main goals are to check safety and see if tumors shrink. The study lasts up to 4 years and involves about 240 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Institute Hospital of JFCR
RECRUITINGTokyo, 135-8550, Japan
-
Centre Leon Berard
RECRUITINGLyon, 69373, France
-
Columbia University
RECRUITINGNew York, New York, 10032, United States
-
Community Health Network
NOT_YET_RECRUITINGIndianapolis, Indiana, 46250, United States
-
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
-
Florida Cancer Specialists - Lake Nona - Sarah Cannon Research Institute
RECRUITINGOrlando, Florida, 32827, United States
-
Florida Cancer Specialists - Sarasota
RECRUITINGSarasota, Florida, 34236, United States
-
Hospital Universitario 12 de Octubre
RECRUITINGMadrid, 28041, Spain
-
Hospital Universitario Vall d'Hebron
RECRUITINGBarcelona, 08035, Spain
-
Institut Gustave Roussy
RECRUITINGVillejuif, 94805, France
-
John Theurer Cancer Center At Hackensack UMC
RECRUITINGHackensack, New Jersey, 07601, United States
-
Kyoto University Hospital
RECRUITINGKyoto, 606-8507, Japan
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
-
NEXT Virginia
RECRUITINGFairfax, Virginia, 22031, United States
-
National Cancer Center Hospital
RECRUITINGTokyo, 104-0045, Japan
-
START Mountain Region
RECRUITINGWest Valley City, Utah, 84119, United States
-
Samsung Medical Center
RECRUITINGSeoul, 06351, South Korea
-
Sarah Cannon Research Institute
RECRUITINGNashville, Tennessee, 37203, United States
-
Severance Hospital, Yonsei University Health System
RECRUITINGSeoul, 03722, South Korea
-
Shanghai East Hospital, Tongji University
NOT_YET_RECRUITINGShanghai, 0200120, China
-
Stanford Cancer Center
RECRUITINGStanford, California, 94305, United States
-
The Ohio State University (OSU) Wexner Medical Center
RECRUITINGColumbus, Ohio, 43210, United States
-
The University of Chicago Medical Center (UCMC)
RECRUITINGChicago, Illinois, 60637, United States
-
Washington University
RECRUITINGSt Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.